Skip to main content
TipRanks
Go Ultimate75% OFF

BrightPath Biotherapeutics Co.Ltd. (4594) Ratios

0 Followers

BrightPath Biotherapeutics Co.Ltd. Ratios

JP:4594's free cash flow for Q4 2025 was ¥0.00. For the 2025 fiscal year, JP:4594's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.

Financial ratios
RatiosMar 26Mar 25Mar 24Mar 23Mar 22
Liquidity Ratios
Current Ratio15.838.146.1821.5714.60
Quick Ratio15.838.146.1821.5714.60
Cash Ratio13.366.165.5420.0012.48
Solvency Ratio-5.52-5.88-4.65-10.97-6.04
Operating Cash Flow Ratio-8.46-9.50-6.06-15.73-8.19
Short-Term Operating Cash Flow Coverage0.00-50.01-10.280.00-17.28
Net Current Asset Value¥ 2.32B¥ 875.69M¥ 929.69M¥ 1.52B¥ 2.46B
Leverage Ratios
Debt-to-Assets Ratio0.000.020.090.000.03
Debt-to-Equity Ratio0.000.030.110.000.03
Debt-to-Capital Ratio0.000.030.100.000.03
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.101.211.261.091.09
Debt Service Coverage Ratio0.00-46.05-10.25-24079.54-16.49
Interest Coverage Ratio0.000.00-825.65-24050.15-4077.44
Debt to Market Cap0.000.010.030.000.02
Interest Debt Per Share0.000.311.780.001.69
Net Debt to EBITDA1.660.680.811.041.53
Profitability Margins
Gross Profit Margin65.48%97.18%-473.61%64.11%78.47%
EBIT Margin-1550632.14%-101434.16%-1619697.22%-28099.85%-9614.55%
EBITDA Margin-1550632.14%-101434.16%-1619147.22%-27783.18%-9386.60%
Operating Profit Margin-1541666.67%-102464.08%-1604276.39%-27785.21%-9579.65%
Pretax Profit Margin-1550632.14%-101434.16%-1619697.22%-28101.00%-9616.90%
Net Profit Margin-1553513.10%-101601.85%-1622336.11%-28136.99%-9632.61%
Continuous Operations Profit Margin-1553513.10%-101601.85%-1622336.11%-28136.99%-9632.61%
Net Income Per EBT100.19%100.17%100.16%100.13%100.16%
EBT Per EBIT100.58%98.99%100.96%101.14%100.39%
Return on Assets (ROA)-50.10%-102.73%-94.95%-87.32%-53.56%
Return on Equity (ROE)-55.10%-124.45%-119.32%-94.77%-58.63%
Return on Capital Employed (ROCE)-53.00%-117.39%-111.15%-90.29%-57.07%
Return on Invested Capital (ROIC)-53.00%-114.49%-100.29%-90.29%-55.20%
Return on Tangible Assets-50.10%-102.73%-94.95%-87.32%-53.56%
Earnings Yield-16.95%-32.10%-27.58%-14.48%-27.71%
Efficiency Ratios
Receivables Turnover0.000.0212.0096.000.93
Payables Turnover0.910.9120.6524.611.73
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover0.000.000.000.000.62
Asset Turnover0.000.000.000.000.01
Working Capital Turnover Ratio0.000.000.000.000.01
Cash Conversion Cycle220561.2920437.3512.74-11.03182.51
Days of Sales Outstanding220964.0520836.5730.423.80392.91
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding402.76399.2217.6814.83210.39
Operating Cycle220964.0520836.5730.423.80392.91
Cash Flow Ratios
Operating Cash Flow Per Share-12.24-15.34-18.03-20.19-29.08
Free Cash Flow Per Share-12.25-15.36-18.15-20.22-29.42
Dividend Paid and CapEx Coverage Ratio-2311.08-912.67-151.27-684.32-85.69
Capital Expenditure Coverage Ratio-2311.08-912.67-151.27-684.32-85.69
Operating Cash Flow Coverage Ratio0.00-50.01-10.280.00-17.28
Operating Cash Flow to Sales Ratio-16260.13-1103.58-16068.33-228.11-98.13
Free Cash Flow Yield-17.75%-34.90%-27.50%-11.75%-28.56%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-5.90-3.12-3.63-6.91-3.61
Price-to-Sales (P/S) Ratio91636.063165.2958815.421943.48347.57
Price-to-Book (P/B) Ratio3.253.884.336.552.12
Price-to-Free Cash Flow (P/FCF) Ratio-5.63-2.87-3.64-8.51-3.50
Price-to-Operating Cash Flow Ratio-5.64-2.87-3.66-8.52-3.54
Price-to-Earnings Growth (PEG) Ratio0.340.140.130.540.17
Enterprise Value Multiple-4.25-2.44-2.82-5.95-2.17
Enterprise Value5.54B2.80B3.29B8.73B3.14B
EV to EBITDA-4.25-2.44-2.82-5.95-2.17
EV to Sales65967.032472.0345692.361653.52203.65
EV to Free Cash Flow-4.06-2.24-2.82-7.24-2.05
EV to Operating Cash Flow-4.06-2.24-2.84-7.25-2.08
Tangible Book Value Per Share21.2311.3515.2626.2748.69
Shareholders’ Equity Per Share21.2311.3515.2626.2748.69
Tax and Other Ratios
Effective Tax Rate-0.00-0.00-0.00-0.00-0.00
Revenue Per Share0.000.010.000.090.30
Net Income Per Share-11.70-14.12-18.21-24.90-28.55
Tax Burden1.001.001.001.001.00
Interest Burden1.001.001.001.001.00
Research & Development to Revenue0.00783.820.00221.3073.72
SG&A to Revenue15417.32241.800.000.000.00
Stock-Based Compensation to Revenue0.000.000.000.000.00
Income Quality1.051.090.990.811.02

Currency in JPY